<DOC>
	<DOCNO>NCT01855880</DOCNO>
	<brief_summary>This Phase IIa , randomise , double-blind , placebo-controlled , multiple dose , multi-center study AbGn-168H subject moderate severe chronic plaque psoriasis.The objective study investigate efficacy , safety , tolerability , pharmacokinetics ( PK ) multiple dose AbGn-168H administer intravenously patient moderate severe chronic plaque psoriasis .</brief_summary>
	<brief_title>Phase IIa Study Multiple Doses AbGn-168H iv Infusion Moderate Severe Chronic Plaque Psoriasis Patients</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>1 . Age 18 75 ( inclusive ) , males female 2 . Body weight &lt; 140 kg 3 . Patients stable moderate severe plaquetype psoriasis , significant change within past 6 month , involve ≥ 10 % body surface area , disease severity PASI ≥ 10 screen visit visit 2 , least 1 lesion target lesion assessment . 4 . Psoriasis disease duration least 6 month prior screen 5 . Patients must candidate systemic psoriasis treatment phototherapy 6 . Patient must give informed consent sign approve consent form prior study procedure 7 . Females childbearing potential must negative pregnancy test result prior enrollment agree use highly effective method birth control study . A highly effective method birth control define one result low failure rate ( le 1 % per year ) . 1 . Patients primary guttatae , erythrodermic , pustular psoriasis patient druginduced psoriasis 2 . Evidence current previous clinically significant disease , medical condition psoriasis , find medical examination ( include vital sign ECG ) , opinion Investigator , would compromise safety patient quality data . This criterion provide opportunity investigator exclude patient base clinical judgment , even eligibility criterion satisfy . ( Psoriatic arthritis consider exclusion ) 3 . HIV infection know HIVrelated Malignancy . 4 . Chronic acute hepatitis B C , carrier status . Patient antiHBc Ab undetectable antiHBs Ab also exclude . 5 . Tuberculosis , positive Tuberculin Skin Test ( TST ) tuberculosis . Subjects previously receive BCG vaccination participate study show negative response InterferonGamma Release Assays ( IGRA ) . 6 . History malignancy past 5 year suspicion active malignant disease except treat cutaneous squamous cell basal cell carcinoma carcinoma situ cervix uterus . 7 . History allergy/hypersensitivity systemically administer biologic agent excipients 8 . Use biologic agent investigational drug within 12 week prior treatment , systemic antipsoriatic medication phototherapy within 4 week prior treatment , topical antipsoriasis medication ( except emollient ) within 2 week prior treatment 9 . Intake restrict medication ( c.f . Section 4.2.2 ) drug consider likely interfere safe conduct study 10 . History alcohol abuse 11 . History drug abuse positive drug screen screen visit . Subjects legitimate medically supervised us drug exclude reason ( section 4.2.2 protocol ) enrol . 12 . Any blood donation significant blood loss within 4 week prior Visit 2 13 . Excessive ( e.g . competitive ) physical activity ( within 1 week prior administration trial ) 14 . Patients follow laboratory value screen consider clinically significant investigator : Haemoglobin , hematocrit , white blood cell count , absolute lymphocyte neutrophil count , platelet count &lt; LLN ( low limit reference normal range ) ALT , AST and/or total bilirubin &gt; 2.5xULN Serum creatinine &gt; 1.5x ULN</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>April 2015</verification_date>
	<keyword>psoriasis</keyword>
	<keyword>dermatology</keyword>
	<keyword>monoclonal antibody</keyword>
</DOC>